AstraZeneca plc (LON:AZN) has been assigned a GBX 6,500 ($81.21) target price by equities research analysts at Societe Generale in a research note issued to investors on Wednesday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock. Societe Generale’s price target would suggest a potential upside of 49.03% from the company’s current price.

Several other equities analysts also recently weighed in on AZN. BNP Paribas reiterated a “neutral” rating and issued a GBX 5,100 ($63.72) price target on shares of AstraZeneca plc in a report on Monday. Goldman Sachs Group Inc. set a GBX 4,000 ($49.98) price target on shares of AstraZeneca plc and gave the stock a “sell” rating in a report on Friday, November 11th. HSBC reiterated a “hold” rating and issued a GBX 4,700 ($58.72) price target on shares of AstraZeneca plc in a report on Friday, November 11th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of AstraZeneca plc in a report on Friday, November 11th. Finally, Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a report on Friday, November 11th. Five equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of GBX 4,929.20 ($61.58).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

AstraZeneca plc (LON:AZN) opened at 4322.50 on Wednesday. The stock’s market cap is GBX 54.68 billion. The firm’s 50-day moving average is GBX 4,794.36 and its 200 day moving average is GBX 4,568.15. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.